Abstract 252P
Background
RS>25 is prognostic for distant recurrence and predictive for adjuvant chemotherapy (aChem) benefit in ER+HER2-negative early breast cancer (BC), independent of tumor size. For patients with tumors >0.5 cm and candidates for aChem, current NCCN guidelines recommend strongly considering OncotypeDX testing and aChem treatment for RS>25. Herein, we sought to evaluate the benefit of aChem in T1a/bN0 early BC patients with high RS>25 tested. We used the Clalit Health Services (CHS) dataset, the largest HMO in Israel, with more than 4.5 million insurers.
Methods
We identified all CHS patients tested between Feb-2006 and Dec-2019 with T1a/bN0 early breast cancer and a RS>25. Demographic, clinicopathological, and treatment data were extracted from the CHS centralized registry. A propensity score matching method based on nearest neighbor with replacements was used to balance differences. Kaplan-Meier analysis with log-rank test was used to test differences in clinicopathological characteristics. Freedom from recurrence of BC locally and at a distant site and freedom from second primary cancer and death also known as invasive disease-free survival (iDFS) between the treatment groups.
Results
159 patients were identified of which 76 patients (47.7%) received aChem. Before applying the propensity- score matching aChem was more common among younger patients >50-years-old (25%) compared with patients ≤70-years-old (7.9)%, healthier patients with Charlson comorbidity score 0-1 (70%) compared with 30.2% for score ≥2, among Oncotype RS >30 72.5%. aChem was more often omitted in invasive lobular carcinoma (75%) and grade 1 tumors (72.7%). Propensity score matching balanced discrepancies among both treatment groups and Kaplan-Meier analysis demonstrated no iDFS improvement with aChem in T1a/bN0 early BC patients with high Oncotype DX recurrence scores (RS>25).
Conclusions
Utility of aChem in T1a-bN0 tumors and RS>25 is dependent on clinocopathologic variables beyond RS. After balancing between these variables no iDFS benefit for aChem was observed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
314P - Concordance of somatic variants between circulating tumor DNA and tissue in patients with breast cancer
Presenter: Kangsu Shin
Session: Poster session 02
315P - Multinational survey study assessing genetic testing and counselling among patients (pts) with breast cancer (MAGENTA): Results on perceptions on testing
Presenter: Sarah Powell
Session: Poster session 02
316P - Comprehensive characterization of the HER2-enriched intrinsic molecular subtype in ER-positive HER2-negative breast cancer
Presenter: Lennart Hohmann
Session: Poster session 02
317P - Awareness of genomic testing among patients with breast cancer in Europe
Presenter: Antonella Cardone
Session: Poster session 02
318P - Evaluation of novel diagnostic kits using the semi-dry dot-blot method combined for detecting metastases in sentinel lymph nodes of patients with breast cancer: A multi-center prospective study
Presenter: Ryota Otsubo
Session: Poster session 02
319P - The impact of low HER2 expression on clinical significances and outcomes in patients with HER2-negative early breast cancer
Presenter: Yumiko Koi
Session: Poster session 02
320P - Clinical and pathological characteristics of breast cancers switching from early luminal-like to metastatic triple-negative phenotype
Presenter: Mariia Ivanova
Session: Poster session 02
321P - Non-BRCA variants in hereditary breast and ovarian cancer patients in the northern Mexico population
Presenter: Dione Aguilar
Session: Poster session 02
322P - Clinicopathological characteristics and genomic profiling of pure mucinous breast cancer
Presenter: Shusen Wang
Session: Poster session 02
323P - Macrophage population analysis of the breast cancer microenvironment within the context of seroma formation after mastectomy (SerMa pilot study)
Presenter: Felicitas Schneider
Session: Poster session 02